Inhalable HUCMSC-Lipo biomimetic formulation inhibits fibroblast activation in mouse and non-human primate pulmonary fibrosis models
Science Bulletin · 2026
DOI: 10.1016/j.scib.2026.08.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Bulletin, 2026. Verfasst von Fangyu Zhao und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, the Fourth Affiliated Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center …. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Fibroblasts, Pulmonary Fibrosis. Die Arbeit nennt 92 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a progressive and fatal lung disorder driven by abnormal fibroblast activation and excessive extracellular matrix (ECM) deposition, leading to structural and functional decline. Existing therapies can slow progression but fail to interrupt fibrotic remodeling. Here, we engineered HUCMSC-Lipo, an inhalable biomimetic formulation fusing human umbilical cord mesenchymal stem cell (HUCMSC) membranes with artificial phospholipids, with formulation parameters systematically optimized using a Bayesian optimization (BO) framework to ensure structural stability and nebulization compatibility. HUCMSC-Lipo maintained membrane functionality and structural integrity for effective nebulized delivery. We successfully established a non-human primate (NHP) PF model and innovatively developed a multidimensional evaluation framework. Utilizing a range of methods, including but not limited to positron emission tomography/computed tomography (PET/CT) molecular imaging with radiolabeled fibroblast activation protein (FAP) inhibitors, we confirmed that HUCMSC-Lipo suppressed fibrotic progression and restored pulmonary function by targeting the regulation of fibroblast activation. Mechanistically, THY-1 enrichment in HUCMSC-Lipo bound integrin receptors to block the FAK/PI3K signaling cascade and restore fibroblast mechanosensitivity, fundamentally turning off the pathological activation "switch" in fibroblasts. Our work presents an inhalable biomimetic formulation that combines therapeutic efficacy with synthetic accessibility, offering a mechanism-targeted approach to PF treatment with strong clinical translatability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, the Fourth Affiliated Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China; Department of…
- Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China; Faculty of Materials Science, Shenzhen MSU-…
- Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China.
- Department of Nuclear Medicine, the Fourth Affiliated Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China.
- Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu 610041, China.
- National and Local Joint Stem Cell Research & Engineering Center for Aging Diseases, Tian Qing Stem Cell Co., Ltd., Harbin 150028, China.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhao, F., Sun, Y., Wang, H., Hou, D., Zhang, R., Xia, W., Zhang, Y., Li, L., Zhao, X., Wang, K., Pan, W., Wang, J., Wang, K., Yang, L., Chen, W., Li, X., Nong, C., Lu, H., Zhang, Y., …, & Sun, X. (2026). Inhalable HUCMSC-Lipo biomimetic formulation inhibits fibroblast activation in mouse and non-human primate pulmonary fibrosis models. Science Bulletin. https://doi.org/10.1016/j.scib.2026.08.013
Vancouver
Zhao F, Sun Y, Wang H, Hou D, Zhang R, Xia W, et al. Inhalable HUCMSC-Lipo biomimetic formulation inhibits fibroblast activation in mouse and non-human primate pulmonary fibrosis models. Science Bulletin. 2026. doi:10.1016/j.scib.2026.08.013
BibTeX
@article{Zhao2026,
author = {Zhao, Fangyu and Sun, Yige and Wang, Haoran and Hou, Dayong and Zhang, Rui and Xia, Wenjing and Zhang, Yongchen and Li, Luyao and Zhao, Xueqi and Wang, Kaiqi and Pan, Wenwen and Wang, Jiannan and Wang, Kai and Yang, Lili and Chen, Wei and Li, Xin and Nong, Chunyang and Lu, Huiying and Zhang, Yi and Zhang, Zhaoyang and Wu, Lina and Han, Zhaoguo and Tang, Ben-Zhong and Sun, Xilin},
title = {Inhalable HUCMSC-Lipo biomimetic formulation inhibits fibroblast activation in mouse and non-human primate pulmonary fibrosis models},
journal = {Science Bulletin},
year = {2026},
doi = {10.1016/j.scib.2026.08.013}
}
EUVIMED